ESPOO, FINLAND - Feb 20, 2017 - Orion Diagnostica is presenting its novel, exclusive, IPR protected, isothermal amplification technology SIBA® at the 24th International Molecular Medicine Tri-Conference 20-22 February 2017 in San Francisco (booth #223). The technology can be used to detect both DNA and RNA targets.
Orion Diagnostica is now offering licensing opportunities for SIBA technology in human IVD and other fields (
link to partnering website
).
Recent studies show that SIBA allows rapid turn around times of less than 15 minutes even for RNA targets (
article link
). The exceptional specificity of SIBA of even 1-2 base pair resolution can be used to distinguish between highly similar targets in eg. strain typing or mutation detection. Rapid assay development of less than four weeks has been proven (
article link
). First CE marked IVD products based on SIBA show excellent performance and robustness employing a low cost device (
article link
). SIBA technology allows the development of a truly cost competive system even for Point-of-Care (POC) or in the field use.
Orion Diagnostica develops, manufactures and markets diagnostic test systems for healthcare professionals with over 40 years of experience. Orion Diagnostica is part of Orion Group, the leading healthcare company in Finland which celebrates its centenary in 2017.
Building well-being is the core of our mission. SIBA® and Orion GenRead® are registered trademarks of Orion Diagnostica Oy.